Because of the first-pass effect induced by oral E, resulting in suppressing the production of IGF-I in liver, oral E users have lower IGF-I levels, followed by increased IR [29], and lower risk of CRC than E nonusers have. Here, IGF1 is linked to colorectal carcinoma.